《大行報告》大和上調康方生物-B(09926.HK)目標價至69.9元 評級「跑贏大市」
大和發表報告指,康方生物-B(09926.HK)於今年5月24日公布已就抗PD-1單抗藥物「派安普利」向美國食品藥品監督管理局(FDA)啟動提交生物製品許可申請,尋求上市批准用於三線治療轉移性鼻咽癌。該行認為是次申請可成集團股價的正面催化劑,相信「派安普利」可成國內首款PD-1獲得美國批准。
大和上調康方生物股份目標價,由58.6元升至69.9元,評級維持「跑贏大市」。不過,大和對該藥的海外收入看法保守,因集團未與美國夥伴簽署許可授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.